ClinConnect ClinConnect Logo
Search / Trial NCT04508244

Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status

Launched by HAMAD MEDICAL CORPORATION · Aug 7, 2020

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Propranolol Troponin Biomarkers Myocardial Injury Brain Injury Trauma Qatar

ClinConnect Summary

The BBTBBT study is researching whether a medication called propranolol, which is a type of beta blocker, can help improve outcomes for patients who have suffered a traumatic brain injury (TBI). This study is particularly focused on patients with different levels of brain injury, from mild to severe. The researchers want to see if giving propranolol early, based on a specific blood test result (high-sensitive troponin T status), can reduce the risk of dying within 10 or 30 days after the injury.

To participate in this study, you need to be an adult between 18 and 65 years old who has experienced a blunt head injury that requires hospital admission. Unfortunately, certain individuals, such as those with severe injuries or specific health conditions, will not be eligible. If you qualify and choose to participate, you will be randomly assigned to receive either the propranolol or a placebo (a harmless substance with no active medication) without knowing which one you are getting. The trial aims to provide clearer evidence on the potential benefits of beta blockers in treating TBI, which could change how these injuries are managed in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All adults (≥18 -65 years)
  • both genders
  • mild-to-severe blunt TBI (head AIS 1-5 and/ GCS 4-15) patients requiring hospital admission
  • Exclusion Criteria:
  • Patients \<18 and\> 65 yrs old
  • penetrating trauma
  • non-survivable injuries (head AIS=6 \& GCS=3)
  • uncontrolled bleeding on arrival to ED
  • pregnant women
  • prisoners
  • patients with heart rate (HR) ≤70, systolic blood pressure (SBP) ≤100 mmHg (or MAP \<70 mmHg) not responding to initial management or required to be maintained on vasopressors on arrival .
  • Patients who will undergo hypothermia therapy,
  • any penetrating injury to head, thorax or abdomen,
  • history of bronchial asthma
  • patients posted for emergency surgery during the first 6 hrs.

About Hamad Medical Corporation

Hamad Medical Corporation (HMC) is a leading healthcare provider in Qatar, dedicated to delivering high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, HMC focuses on innovative healthcare solutions that enhance patient outcomes and contribute to the global medical knowledge base. With a robust infrastructure and a commitment to ethical research practices, HMC collaborates with local and international partners to conduct trials across various therapeutic areas, aiming to address pressing health challenges and improve the standard of care within the community. Through its research initiatives, HMC strives to foster a culture of scientific inquiry and evidence-based medicine, ultimately benefiting patients and the healthcare system at large.

Locations

Doha, , Qatar

Patients applied

0 patients applied

Trial Officials

Ayman El-Menyar, MD

Principal Investigator

Hamad Medical Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials